Literature DB >> 7679347

Pseudomonas cepacia in lung transplant recipients with cystic fibrosis.

G I Snell1, A de Hoyos, M Krajden, T Winton, J R Maurer.   

Abstract

Twenty-four isolated double lung transplants (LTXs) have been performed in 22 patients with cystic fibrosis, with a follow-up of 4 to 47 months. Prior to LTX, all patients were colonized with Pseudomonas aeruginosa, and ten patients were also colonized with Pseudomonas cepacia. Both organisms were specifically sought before LTX. All patients who grew P cepacia before LTX did so after LTX. Five additional patients only grew this bacterium after LTX. There was no difference between those who grew P cepacia and those who did not in terms of data before LTX for age, weight, pulmonary function, and 6-min walk. After LTX, 7 of the 15 patients who had ever grown P cepacia died. No patient who grew only P aeruginosa died. The median survival in the subgroup with P cepacia was 28 days. Five of the seven died as a direct result of P cepacia pneumonia and sepsis. One died of cyclosporin A (cyclosporine) neurotoxicity with concurrent P cepacia pneumonia, and one died at the time of a retransplant for graft failure (associated with three bouts of P cepacia pneumonia and cytomegalovirus). Four of seven had not grown this bacterium before LTX. There were no perioperative factors, including antibiotic choices, that distinguished survivors and nonsurvivors. Overall 1-year survival is about 70 percent (15/22). Fourteen bouts of P cepacia pneumonia occurred in 12 patients. Four empyemas, one lung abscess, one suppurative pericarditis, and five cases of sinusitis were also due to this bacterium. In conclusion, P cepacia is responsible for excess morbidity and mortality after LTX. This organism is particularly lethal if isolated for the first time after LTX. Factors predicting its acquisition in this setting are unknown. While it is possible that the facial sinuses may act as an unrecognized reservoir or that patients or equipment provide a source, further study into the epidemiology of this organism is necessary to improve the survival of colonized patients undergoing LTX.

Entities:  

Mesh:

Year:  1993        PMID: 7679347     DOI: 10.1378/chest.103.2.466

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  29 in total

1.  Isolation of Burkholderia cepacia by enrichment.

Authors:  P G Flanagan; A Paull
Journal:  J Clin Pathol       Date:  1998-07       Impact factor: 3.411

2.  Lung donors for cystic fibrosis patients.

Authors:  J J Egan; K Webb; A A Woodcock
Journal:  Thorax       Date:  1996-08       Impact factor: 9.139

Review 3.  Lung transplantation: infection, inflammation, and the microbiome.

Authors:  Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

Review 4.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 5.  Should patients with cystic fibrosis infected with Burkholderia cepacia undergo lung transplantation?

Authors:  A K Webb; J Egan
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

Review 6.  Lung transplantation. Part II. Postoperative management and results.

Authors:  D E Wood; G Raghu
Journal:  West J Med       Date:  1997-01

7.  Lung transplantation for cystic fibrosis.

Authors:  Frederick R Adler; Paul Aurora; David H Barker; Mark L Barr; Laura S Blackwell; Otto H Bosma; Samuel Brown; D R Cox; Judy L Jensen; Geoffrey Kurland; George D Nossent; Alexandra L Quittner; Walter M Robinson; Sandy L Romero; Helen Spencer; Stuart C Sweet; Wim van der Bij; J Vermeulen; Erik A M Verschuuren; Elianne J L E Vrijlandt; William Walsh; Marlyn S Woo; Theodore G Liou
Journal:  Proc Am Thorac Soc       Date:  2009-12

8.  Selective media for isolation of Burkholderia (Pseudomonas) cepacia from the respiratory secretions of patients with cystic fibrosis.

Authors:  N Cimolai; C Trombley; A G Davidson; L T Wong
Journal:  J Clin Pathol       Date:  1995-05       Impact factor: 3.411

9.  Accuracy of four commercial systems for identification of Burkholderia cepacia and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis.

Authors:  D L Kiska; A Kerr; M C Jones; J A Caracciolo; B Eskridge; M Jordan; S Miller; D Hughes; N King; P H Gilligan
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

10.  Pulmonary evolution of cystic fibrosis patients colonized by Pseudomonas aeruginosa and/or Burkholderia cepacia.

Authors:  I Jacques; J Derelle; M Weber; M Vidailhet
Journal:  Eur J Pediatr       Date:  1998-05       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.